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Abstract Severe combined immunodeficiency (SCID) is
one of the most severe forms of primary immunodeficiency
characterized by absence of functional T lymphocytes. It is
a paediatric emergency, which is life-threatening when
recognized too late. The clinical presentation varies from
the classical form of SCID through atypical SCID to
Omenn syndrome. In addition, there is a considerable
immunological variation, which can hamper the diagnosis.
In this educational review, we describe the immunopatho-
logical background, clinical presentations and diagnostic
process of SCID, as well as the therapeutic possibilities.
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Abbreviations
GVHD Graft versus host disease
HSCT Hematopoietic stem cell transplantation
NHEJ Non-homologous end joining
PID Primary immunodeficiency
SCID Severe combined immunodeficiency
Introduction
Severe combined immunodeficiency (SCID) is an inherited
primary immunodeficiency, which is characterized by the
absence or dysfunction of T lymphocytes affecting both
cellular and humoral adaptive immunity [46]. It is one of
the most severe forms of primary immunodeficiency (PID),
which is life-threatening when recognized too late. Seven
percent of PID patients suffer from a T cell deficiency,
including SCID [18]. Depending on the genetic defect, B
and natural killer (NK) cells may be present or absent.
Conventionally, SCID can be classified as T−B+ and T−B−
SCID with further subdivision based on the presence or
absence of NK cells. However, the presentation is not
always classic, and the presence or absence of NK cells
may be misleading. Therefore, a phenotype describing NK
cells no longer forms a part of the classification system of
the International Union of Immunological Societies [47]. It
has become clear that clinical presentation has wide
phenotype variability with considerable immunological
variation [43]. These aspects can impede the diagnosis of
SCID. In this review, we address the immunological and
clinical spectrum of SCID and provide some clues and tools
for diagnosing SCID.
Clinical presentations of SCID
Classical SCID
A family history of unusual or fatal infective complications or
unexplained infant death is important, particularly in consan-
guineousfamilies;ahistoryofaffectedmalerelativessuggests
common gamma chain-deficient SCID. Affected infants
generally appear well at birth, but within the first few months
of life, demonstrate failure toclear infections and present with
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failure to thrive and, sometimes, apparent food intolerance
(Table 1)[ 20]. Persistent respiratory tract infection is
common, with failure to clear viruses accompanying
persistent bronchiolitic-like signs. Insidiously progressive
respiratory disease with radiological evidence of interstitial
pneumonitis and hyperinflation suggests Pneumocystis jiroveci
infection, which may be a co-pathogen with respiratory
viruses (Fig. 1)[ 4]. Persistent viral diarrhoea with failure to
thrive is an important sign. Although patients with SCID are
often initially well and growing normally, they fall away from
the growth centile after a few months when infection occurs
because of intestinal villous atrophy, leading to malabsorption,
w h i c hi ns e v e r ec a s e sr e s u l t si nm a l n u t r i t i o n .
Bacterial infections are less common in part because of the
presenceofmaternalIgGinearlyinfancy.However,prolonged
otitis media and invasive bacterial infections, such as
staphylococcal or pseudomonas septicaemia and pneumonia,
may occur, which may respond poorly to appropriate
treatment. However, patients with associated agranulocytosis,
such as those with reticular dysgenesis due to adenylate kinase
2 (AK2) deficiency, generally present in the first few days of
life with omphalitis or invasive bacterial sepsis [5].
Severe invasive fungal infection is rare, but often fatal.
Extensive persistent superficial candidiasis is more common.
Disseminated BCGosis occasionally may be the presenting
feature in immunised infants. Skin lesions demonstrate acid
fast bacilli on histological analysis. A mild reticular skin rash,
which may be thickened and lichenoid, with or without
slightly deranged liver function tests may be seen in
maternofoetal graft versus host disease. As SCID infants lack
functional T cells, they cannot reject foreign lymphocytes
acquiredfromthemotherinutero,andsotheskinisinfiltrated
by abnormal maternal T lymphocyte clones [41]. A similar
clinical picture may occur in patients who have received an
unirradiated blood transfusion, due to viable donor lympho-
cytes in the red cell donation, although in these cases, the
rash is more severe and lymphadenopathy and hepatosple-
nomegaly may be present.
Examination usually reveals a wasted child who has
dropped through the weight centiles—head circumference
is usually preserved. There may be abdominal distension
and muscle wasting due to malabsorption and malnutrition.
Respiratory signs may include tachypnoea, nasal flaring,
subcostal and intercostal recession, with widespread crep-
itations and rales, and cyanosis. There may be evidence of
oral or perineal candidiasis and other superficial infections.
There is no clinically detectable lymphoid tissue, although
detecting this in young infants is not easy because lymph
nodes and tonsils in normal infants are often very small.
There may be hepatomegaly, with or without splenomegaly,
particularly when disseminated Bacille Calmette–Guerin
(BCG) infection is present. Rare presentations include
Hodgkin-like polymorphous lymphoproliferative disorder,
with rapidly growing extranodal tumours [57]. Very rarely,
erythrophagocytosis has been described, in association with
maternal T lymphocyte engraftment.
Omenn syndrome
Omenn syndrome is characterised by a generalised thick-
ened erythematous rash, often with scaling and erythema-
tous exfoliating, protein-losing erythroderma, developing a
“leathery” consistency (Fig. 2). Hair, including eyebrows
and eyelashes, is usually lost as the rash evolves. The rash
may be present at birth or evolve over the first few weeks of
life. There is an associated lymphadenopathy, particularly of
the axillary and inguinal nodes. Hepatosplenomegaly is a
frequent finding. There are raised serum IgE levels with a
marked eosinophilia and combined immunodeficiency [71].
Children usually suffer from diarrhoea, failure to thrive and
persistent infection as seen in other forms of SCID—
staphylococcal or pseudomonas skin infection are particularly
common. Affected infants are often miserable because of the
Table 1 Presenting features of classical and atypical severe combined immunodeficiency and Omenn syndrome
Classical SCID Omenn syndrome Atypical SCID
Present in infancy Present in infancy Present >12 months of age
Persistent viral respiratory +/−
gastrointestinal infection
Erythroderma Recurrent, severe, prolonged viral infection
Pneumocystis jiroveci pneumonitis Alopecia bronchiectasis
Disseminated BCG infection Hepatosplenomegaly Autoimmune cytopenias
Failure to thrive Massive lymphadenopathy Failure to thrive
Superficial candidiasis Inflammatory pneumonitis/enteritis Granulomatous cutaneous lesions
Maternofoetal graft versus host disease Raised IgE EBV-associated lymphoproliferation
Absent lymphoid tissue Eosinophilia Partial or restricted antigen-specific antibody responses
Absent immunoglobulins Lymphocytosis Lymphopenia
Absent T lymphocytes
562 Eur J Pediatr (2011) 170:561–571high levels of circulating inflammatory cytokines. Pneumo-
nitis and enteritis may be predominantly inflammatory rather
than infective. The clinical picture may resemble SCID with
maternofoetal engraftment; molecular genetic studies to
identify the origin of the dermal infiltrative T lymphocytes
can differentiate the two disorders [2]. Originally described in
patients with mutations in recombinase activation genes
(RAG) 1 and 2, mutations in a number of different genes
have subsequently been described, including artemis, IL7Ra,
RMRP, 22q11 deletion, CHD7, DNA ligase IV (LIG4),
adenosine deaminase (ADA) and interleukin 2 receptor,
gamma (IL2RG) [71].
Atypical SCID
Patients may present with atypical forms of SCID or Omenn
syndrome. Previously described as profound combined
immunodeficiency, these patients usually survive beyond
12 months of age. Increasingly, hypomorphic mutations in
genes normally associated with classical SCID are identified,
thus retaining some protein function. Alternative mechanisms
of demonstrating partial immunity include spontaneous gene
reversion in early lymphoid progenitors [52, 59, 60, 74].
Such patients present with severe, prolonged infection,
which may slowly resolve. Partial antibody responses can
be demonstrated to restricted antigens. Other presentations
include autoimmune manifestations, particularly with auto-
immune cytopenias, and EBV-driven lymphoproliferative
tumours. Rarely, cutaneous granulomatous lesions have been
described [16, 19, 30, 32, 55]. It is important to consider
atypical SCID presentations in children presenting beyond
the first year of life so that appropriate antimicrobial
treatment can be commenced and the patient considered for
curative therapy (vide infra).
Other forms of SCID
In addition to SCID caused by developmental defects, SCID
can also be caused by mutations affecting lymphocyte
survival, as seen in patients with reticular dysgenesis due to
mutations in AK2 [48] and in the enzyme deficiencies ADA
and purine nucleoside phosphorylase (PNP), involved in
nucleotide metabolism and salvage [3, 12]. As a result of the
deficiency, toxic metabolites are formed, to which lympho-
cytes are exquisitely sensitive. Consequently, ADA and PNP
deficiencies usually lead to profound lymphopenia [54].
Finally, several deficiencies have been described that can
give rise to a clinical phenotype of SCID, but only affect a
subset of T cells, e.g. MHC class II deficiency, ZAP 70
kinase deficiency [47]( [ 62] #1755). Additionally, defects in
CD154 (CD40 ligand) and CD40 may present in infancy
with P. jiroveci pneumonia. These types of SCID will not be
further discussed in this review.
Stepwise diagnostics for SCID
Flow cytometric immunophenotyping of peripheral blood
The first step in the diagnostic process in a patient
presenting with features consistent with SCID is ruling
Fig. 2 A newborn infant with Omenn’s syndrome due to a mutation
in the RAG 1 gene. Note the confluent erythematous exfoliating,
thickened rash with a “leathery” consistency and loss of hair and
eyebrows (courtesy of The Paediatric Immunology Unit, Great North
Children’s Hospital, Newcastle upon Tyne)
Fig. 1 Chest radiograph from a 5-month-old infant with severe
combined immunodeficiency showing bilateral patchy shadowing
secondary to interstitial pnuemonitis due to infection with respiratory
syncytial virus and Pneumocystis jiroveci. There is hyperinflation of
the lungs, and the midline pleural borders of the upper lobes are
visible because the thymic shadow is absent (courtesy of The
Paediatric Immunology Unit, Great North Children’s Hospital, New-
castle upon Tyne)
Eur J Pediatr (2011) 170:561–571 563out HIV infection [17]. When HIV has been excluded, a
blood smear differential may demonstrate lymphocytopenia,
which is suggestive of SCID [28]. It should be noted,
however, that a normal lymphocyte count on the differential
white cell count does not exclude SCID because the absolute
number of lymphocytes may be normal, but lymphocyte
subsets may be severely reduced or absent. Therefore, flow
cytometric immunophenotyping of lymphocyte subsets in
peripheral blood is an important screening assay. In classical
SCID, the various types can easily be discriminated (Fig. 3a)
with a straightforward analysis of B, T and NK cells. For
correct interpretation, reference values of age-matched
controls should be used [13].
Interpretation of results is more complicated in Omenn
syndrome or atypical SCID. These patients present with
high numbers of oligoclonal T cells [14], the presence of
which may be misleading, and so detailed analysis of T
cells in patients clinically suspected for typical or atypical
SCID is of utmost importance [71].
Gene defects and disease mechanisms in T−B+ SCID
T−B+ SCID is caused by mutations in cytokine-mediated
signalling. The majority of patients have X-linked SCID
caused by mutations in the IL2RG gene encoding the
common γ chain (γc). The γc chain is shared by the IL2,
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A Fig. 3 Flow cytometric analysis
of peripheral blood and bone
marrow of SCID patients.
a Flow cytometric analysis of
lymphocyte subsets in peripher-
al blood of SCID patients can
be used for definition of the type
of SCID and guides molecular
diagnostics. b For B− SCID
patients, flow cytometric
analysis of the bone marrow
precursor B cell compartment
delineates the precursor B cell
differentiation block, which can
be helpful in candidate gene
selection
564 Eur J Pediatr (2011) 170:561–571IL4, IL7, IL9, IL15 and IL21 cytokine receptors [31].
Cytokines mediate oligomerization of the γc chain with the
appropriate cytokine receptor chain, which leads to Janus
kinase 1 (JAK1) and Janus kinase 3 (JAK3) activation and
phosphorylation of critical tyrosine residues in the receptor
chains (Fig. 4)[ 23, 36]. JAK1 and JAK3 phosphorylate
each other and phosphorylate STAT5. Upon phosphorylation,
STAT5 dimerizes and translocates to the nucleus where it
activates multiple genes [37]. Autosomal recessive forms of
T−B+ SCID are less frequent and have been shown to be
caused by mutations in the JAK3 or IL7RA genes [38, 50].
Mutations in the IL7RA gene abrogate T cell development,
but do not interfere with NK cell development.
A separate category of T−B+ SCID patients have
mutations in one of the four CD3 genes (CD3G, CD3D,
CD3E and CD3Z)[ 21, 52]. The CD3 complex is composed
of one CD3γ, CD3δ and CD3ε chain and two CD3ζ chains
(Fig. 4b). The absence of one of the CD3 chains inhibits
formation of the CD3 complex and consequently expression
and signalling via (pre)Tcell receptors.
Gene defects and disease mechanisms in T−B− SCID
Patients with T−B− SCID generally have a defect in V(D)J
recombination [15]. This process takes place in developing
B and T cells and is responsible for the rearrangement of
the immunoglobulin and T cell receptor genes (Fig. 5).
Different steps of V(D)J recombination can be discriminat-
ed. In the first step, proteins encoded by the recombination
activating genes (RAG1 and RAG2) form a heterodimer
and make a single-stranded nick between a coding element
(Variable (V), Diversity (D), or Joining (J) gene segment
and the recombination signal sequence (RSS) [69], result-
ing in the formation of a hairpin-sealed coding end at the
side of the coding element and a blunt signal end at the
RSS side (Fig. 4). In the second phase, which is referred to
as the processing phase, the DNA–protein kinas (PK)
complex, composed of Ku70, Ku80 and DNA–PKcs, binds
to the hairpin-sealed coding end and phosphorylates
Artemis, which subsequently opens the hairpin. Further
processing of the DNA ends takes place, i.e. nucleotide
deletions, random non-templated insertions of nucleotides
by TdT before the ends, are ligated by LIG4/XRCC4 in
conjunction with Cernunnos/XLF. The first phase of V(D)J
recombination is lymphoid specific, while the processing
and ligation phase are carried out by the ubiquitously
expressed components of the non-homologous end-joining
pathway (NHEJ) of DNA double-strand breaks [70]. If a
mutation occurs in one of the NHEJ factors, the patients not
only have defective V(D)J recombination but also a general
DNA DSB repair defect, which results in increased
sensitivity to ionizing radiation. Mutations have been
identified in RAG1, RAG2, Artemis and DNA–PKcs
giving rise to typical and atypical SCID [40, 56, 64].
Mutations in LIG4 can give either rise to T−B− SCID or
the LIG4 syndrome, which is characterized by microceph-
aly and growth retardation [26, 65]. Mutations in XLF
(Cernunnos) also give rise to these manifestations [9].
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Eur J Pediatr (2011) 170:561–571 565Detailed analysis of T cells potentially present in patients
suspected for having typical or atypical SCID
There are several reasons for the presence of T cells in
SCID patients. First, Tcells can be engrafted transplacentally
fromthemother.In50%ofB−SCIDandin80%ofB+SCID,
maternal T cells can be detected [41]. These T cells can be
present at low frequencies, but can also exceed the upper
limit of reference. The immunophenotype of these T cells
can be diverse. Most have a mature (CD45RO+) phenotype,
but this cannot be regarded as a golden rule. They may have
a disturbed CD4/CD8 ratio or aberrant CD3 expression (van
der Burg, unpublished observation). To prove that Tcells are
maternal, they can be analysed by human leukocyte antigen
(HLA) typing or the origin determined by XY FISH in case
of boys, or short tandem repeat analysis can be performed
[41, 68].
Patients with Omenn syndrome have hypomorphic
mutations resulting in the presence of T cells that expanded
in the periphery [72]. These T cells are autologous and
generally oligoclonal. The clonality of the T cells can be
determined by flow cytometry, e.g. by using a Vβ analysis
kit [63]. Molecular clonality assays by heteroduplex
analysis or spectratyping are alternative methods which
reliably determine whether the Tcells present are oligoclonal,
polyclonaloroligoclonalinapolyclonalbackground[34, 35].
The latter would be predominantly due to infections.
A much rarer explanation for the presence of autologous
T cells in SCID patients is the occurrence of somatic
reversion mutations [73]. These reversion mutations have
been described in a few X-linked SCID cases, in a single
RAG deficiency and in patients with a CD3Z deficiency
[52, 59, 60, 74]. In these patients, somatic reversion
mutation occurred, probably in early T cells, and corrected
the genetic defect. If somatic reversion occurs, the T cells
have a selective growth advantage and the potential to
develop normal function. The mechanism by which this
somatic reversion arises is as yet unknown.
T cells in patients with suspected typical or atypical
SCID should always be typed in detail. Analysis of TCR
expression can be particularly helpful. In some patients
with a partial V(D)J recombination defect, a high frequency
of TCRγδ T cells is detected [19].
Analysis of protein expression of candidate genes
In T−B+ SCID, analysis of CD132 expression on lympho-
cytes and measurement of STAT5 phosphorylation upon IL2
stimulationsandinformativescreeningtestsareadvanced[25,
75]. If CD132 expression is absent, this is indicative of X-
linked SCID, and in virtually all cases without CD132
expression, a mutation is found in the IL2RG gene. The
same holds true for the analysis of IL7RA expression. This is
somewhat more complicated because IL7Rα is mainly
expressed on T cells, which are typically absent in these
patients. Aberrant results in STAT5 phosphorylation [75]
point toward defects downstream of the γc chain, and if
aberrant, sequence analysis of JAK3 is a logical choice for
molecular analysis.
Flow cytometric analysis of precursor B cell compartment
in bone marrow
In the case of T−B− SCID, analysis of the precursor B cell
compartment in bone marrow can give information whether
or not there is an underlying defect in the V(D)J
recombination process. A typical SCID patient with a V
(D)J recombination defect due to mutations in RAG1,
RAG2, Artemis or DNA–PKcs has a full block in precursor
B cell differentiation before the cytoplasmic Igμ-positive
pre-B-II cell stage (Fig. 3b)[ 44, 45, 64]. In a hypomorphic
mutation, the differentiation block can be incomplete,
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Fig. 5 A schematic representa-
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V(D)J recombination process
and the involved molecules
566 Eur J Pediatr (2011) 170:561–571implying that low frequencies of pre-B-II can be present.
Alternatively, an incomplete precursor B cell differentiation
block can be due to the type of gene defect. LIG4 and XLF
deficiencies give rise to the presence of pre-B-II and
immature B cells and even mature B cells in XLF
deficiency [30, 65].
Sequence analysis of candidate genes
Based on the clinical presentation and the immunopheno-
type, a candidate gene is selected, and the gene is
sequenced to identify a mutation [66]. The frequency of
mutations in T−B+ and T−B− SCID are depicted in Fig. 6.
For some genes, e.g. RAG1, RAG2 and Artemis, in vitro
function tests can be used to determine the level of
(reduced) enzymatic activity of the mutation [49, 67]. In
T−B− SCID patients without a defect in the RAG1 or RAG2
gene, it is important to determine whether the patient is
sensitive for ionizing radiation and consequently has a
defectinthe NHEJpathwayusinga clonogenicsurvivalassay
on fibroblasts cultured from a skin biopsy [40, 56, 64].
Analysis of the coding joints of immunoglobulin gene
rearrangements in bone marrow precursor B cells, in vivo
V(D)J recombination studies, is a valuable tool in the
diagnostic process of radiosensitive T−B− SCID patients
because it can give a clue which step in the V(D)J
recombination assay is affected [64, 65, 67]. The latter tests
are not routinely done in a diagnostic setting, but can be of
importance in more complicated cases.
Supportive management
Infants suspected of having a severe immunodeficiency
disorder should be placed in protected isolation, limiting the
numbers of persons involved with care; specifically,
individuals with respiratory or gastrointestinal symptoms
of infection should avoid contact. If the mother is
cytomegalovirus (CMV)-negative, breastfeeding should be
encouraged—otherwise, it should be discontinued to
prevent neonatal CMV infection from being transmitted
through breast milk. Strict handwashing procedures are
critical to prevent infection. Blood products should be
CMV-negative and irradiated to avoid the risk of transfu-
sion GVHD [61]. Appropriate imaging of chest, abdominal
organs and brain should be considered, guided by the
clinical features. For those diagnosed later, particular
attention needs to be paid to nutritional status and the
management of dietary intolerances secondary to infectious
or inflammatory gastrointestinal problems. Advice from
paediatric gastroenterologists should be sought early, to
minimise the impact of the disease on the gut and to
institute modular formula milk feeds or parenteral nutrition
as appropriate. Respiratory paediatricians should be con-
sulted early to maximise supportive therapy and prevent
further lung damage. Imaging to detect focal infiltration is
important and may guide subsequent biopsy. Infection
should be sought aggressively, and biopsy material may
be required to demonstrate infection. Culture of appropriate
tissue specimens, including bronchoalveolar lavage fluid,
and PCR may be needed to identify infecting pathogens—
serology is generally unhelpful. Infections should be
vigorously treated—broad spectrum multi-agent antimicro-
bial therapy may be required. Co-trimoxazole as prophylaxis
against P. jiroveci should be given. Antifungal prophylaxis
should also be used, and antiviral prophylaxis with aciclovir
is used in patients with a previous herpes simplex infection.
Supporting the emotional needs of the family is also very
important.
Curative therapy
Hematopoeitic stem cell transplantation (HSCT) is the
treatment of choice for patients with SCID. If HSCT with
conditioning chemotherapy is embarked upon, isolation in
facilities with positive-pressure-filtered air supply is necessary,
mainly to reduce the risk of aspergillosis and droplet-borne
viralinfections.EuropeandataregardingoutcomeofHSCTfor
SCID Patient data are collected in the Stem Cell Transplanta-
tion for Immunodeficiencies in Europe registry, giving data on
almost 700 patients, and have recently been published [24]. A
broad repertoire of stem cell sources are used, including stem
cells from marrow, mobilised peripheral blood stem cells or
those harvested from umbilical cord blood. Best results are
B+ SCID B- SCID
DNA-PKcs
XLF
LIG4
RAG1/2
Artemis
CD3
IL7RA
IL2RG
JAK3
Fig. 6 Distribution of B+ SCID
(n=159 patients) and B− SCID
(n=136 patients) in Europe
according to the ESID patient
registry 2010 (http://www.esid.
org/statistics.php?sub=2).
ESID, European Society for
Immunodeficiencies
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around 90% in the best circumstances. The molecular defect
has a bearing on outcome, with B− SCID patients having an
overall worse outcome than B+ forms of SCID [42]. The
outcome is better in the absence of infection, arguing for the
early identification of patients through neonatal screening
programmes [8]. New chemotherapy conditioning regimens
are increasingly utilised, with improved outcome. A success-
ful procedure is generally curative, with patients leading
normal lives off medication, but few long-term studies have
demonstrated long-term sequelae for some patients [39, 58].
Particular problems relate to ongoing thymopoiesis, with
failure leading to T lymphocyte senescence in the long term
[7, 10]. Long-term immunoglobulin therapy is necessary for
some B lymphocyte dysfunction or failure of donor engraft-
ment. Chemotherapy may lead to infertility. Hypothyroidism,
secondary to chemotherapy, affects about 10% of patients.
Some sequelae relate to the specific genetic defect, for
instance, human papillomavirus-associated warts in IL2RG/
JAK3 SCID [33] and neurodevelopmental disorders in ADA
deficiency [53].
For ADA deficiency, enzyme replacement therapy with
polyethelyne-glycosylated ADA is an alternative treatment
[29]. Treatment is required lifelong, is expensive and results
in only partial immune reconstitution. Sequalae include the
development of autoimmunity, but in the short term, it may
allow some immune reconstitution and clearance of
infection before proceeding to definitive therapy.
Gene therapy has been used for ADA- and IL2RG-
deficient SCID [1, 6, 11]. Advantages include removal of
the necessity for chemotherapy conditioning and available
treatment despite lack of a matched donor. Earlier ADA
trials were only partially successful, and the majority of
patients required ongoing PEG-ADA therapy. More recently,
the procedure has been more successful, although low doses
of chemotherapy give the best results [22]. Some patients
have an ongoing requirement for immunoglobulin replace-
ment. XL-SCID gene therapy does not require chemotherapy
and has led to complete immune reconstitution, but insertion
of the retroviral vector close to oncogenes has led to the
development of lymphoproliferation in some patients [27].
Development of new, probably safer, vectors and directed
insertion of the mutated gene away from oncogenes promise
improved outcome, and clinical trials are ongoing [51].
Treatment of other forms of SCID is at a pre-clinical phase.
Concluding remarks
SCID is one of the most severe forms of primary
immunodeficiency and is a paediatric emergency, which is
life-threatening if recognized too late. Therefore, early
diagnosis and good clinical management are crucial. The
clinical and immunological spectrum of SCID is broader
than initially described, so (atypical) SCID should be
considered as a potential diagnosis more often. Improved
supportive care, detection of infection by molecular means
and less toxic chemotherapy conditioning regimens have
significantly improved survival, and patients should be
referred urgently to centres specializing in the diagnosis and
treatment of such patients to optimize outcome.
Learning points
▪ SCID is one of the most severe forms of PID and is a life-
threatening paediatric emergency.
▪ The molecular basis of most forms of SCID is now
recognized.
▪ Early careful liaison with the immunology laboratory
will enable the most appropriate investigations to be
performed.
▪ Atypical, later presentation of patients with partial gene
function is increasingly described.
▪ Atypical SCID should be considered in patients presenting
with unusual, severe or recurrent infections.
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